Arbutus Biopharma Corporation (NASDAQ: ABUS) is -32.73% lower on its value in year-to-date trading and has touched a low of $0.82 and a high of $3.66 in the current 52-week trading range. The ABUS stock was last observed hovering at around $1.87 in the recent trading session, with the current gains setting it 0.03% off its average median price target of $5.00 for the next 12 months. It is also 81.0% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are 52.5% higher than the price target low of $4.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $1.90, the stock is -0.74% and 4.37% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.32 million and changing 1.60% at the moment leaves the stock -3.15% off its SMA200. ABUS registered -16.89% loss for a year compared to 6-month loss of -39.29%. The firm has a 50-day simple moving average (SMA 50) of $2.0182 and a 200-day simple moving average (SMA200) of $2.1877.
The stock witnessed a -8.33% gain in the last 1 month and extending the period to 3 months gives it a 105.47%, and is -3.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.42% over the week and 8.75% over the month.
Arbutus Biopharma Corporation (ABUS) has around 80 employees, a market worth around $125.53M and $6.80M in sales. Distance from 52-week low is 131.31% and -48.09% from its 52-week high. The company has generated returns on investments over the last 12 months (203.20%).
Arbutus Biopharma Corporation (ABUS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Arbutus Biopharma Corporation (ABUS) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Arbutus Biopharma Corporation is expected to release its quarterly report on 07/30/2020 and quarterly earnings per share for the current quarter are estimated at -$0.23 with sales reaching $1.44M over the same period.The EPS is expected to shrink by -137.80% this year.
Arbutus Biopharma Corporation (ABUS) Top Institutional Holders
63 institutions hold shares in Arbutus Biopharma Corporation (ABUS), with 20.8M shares held by insiders accounting for 30.16% while institutional investors hold 50.17% of the company’s shares. The shares outstanding are 67.68M, and float is at 44.46M with Short Float at 1.29%. Institutions hold 35.04% of the Float.
The top institutional shareholder in the company is RTW Investments LP with over 6.87 million shares valued at $6.94 million. The investor’s holdings represent 9.96% of the ABUS Shares outstanding. As of Mar 30, 2020, the second largest holder is Cowen and Company, LLC with 4.33 million shares valued at $4.37 million to account for 6.28% of the shares outstanding. The other top investors are Citadel Advisors LLC which holds 2.48 million shares representing 3.59% and valued at over $2.5 million, while Morgan Stanley holds 2.97% of the shares totaling 2.05 million with a market value of $2.07 million.
Arbutus Biopharma Corporation (ABUS) Insider Activity
A total of 0 insider transactions have happened at Arbutus Biopharma Corporation (ABUS) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Arbutus Biopharma Corporation (ABUS): Who are the competitors?
The company’s main competitors (and peers) include PDL BioPharma Inc. (PDLI) that is trading 13.49% up over the past 12 months. Short interest in the company’s stock has risen 25.03% from the last report on May 14, 2020 to stand at a total of 0.43 million short shares sold with a short interest ratio of 0.31.